Zevra Therapeutics Stock Forecast

Sell candidate since Jun 05, 2026

The Zevra Therapeutics, Inc. stock price fell by -5.01% on the last day (Friday, 5th Jun 2026) from $11.17 to $10.61. During the last trading day the stock fluctuated 7.92% from a day low at $10.36 to a day high of $11.18. The price has risen in 6 of the last 10 days and is up by 1.14% over the past 2 weeks. Volume has increased on the last day by 1 million shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 2 million shares were bought and sold for approximately $22.45 million.

The stock lies in the lower part of a very wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $10.08 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 15.82% during the next 3 months and, with a 90% probability hold a price between $11.67 and $14.76 at the end of this 3-month period.

ZVRA Signals & Forecast

There are few to no technical positive signals at the moment. The Zevra Therapeutics, Inc. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. On corrections up, there will be some resistance from the lines at $11.16 and $10.65. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Thursday, May 14, 2026, and so far it has fallen -9.01%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Support, Risk & Stop-loss for Zevra Therapeutics, Inc. stock

Zevra Therapeutics, Inc. finds support from accumulated volume at $10.49 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.82 between high and low, or 7.92%. For the last week, the stock has had daily average volatility of 5.01%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (ZVRA) For The Upcoming Trading Day Of Monday 8th

For the upcoming trading day on Monday, 8th we expect Zevra Therapeutics, Inc. to open at $10.71, and during the day (based on 14 day Average True Range), to move between $10.32 and $10.90, which gives a possible trading interval of +/-$0.575 (+/-5.57%) up or down from last closing price. If Zevra Therapeutics, Inc. takes out the full calculated possible swing range there will be an estimated 5.57% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $10.49 (1.13%) than the resistance at $11.06 (4.24%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Zevra Therapeutics, Inc. stock A Buy?

The Zevra Therapeutics, Inc. stock holds several negative signals and despite the positive trend, we believe Zevra Therapeutics, Inc. will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Strong Sell candidate.

Current score: -5.162 Strong Sell Candidate Downgraded

Predicted Fair Opening Price

Predicted fair opening price on June 8, 2026 - $10.71 ( 0.97%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk